Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...

NEW YORK – Researchers have identified a gene signature that can predict whether early-stage breast cancer patients will ...

October 1, 2024–Celebrate the magnificence of horses during Horse Week 2024, an online film festival proudly presented by ...

Find out how this could enhance access to quality healthcare, with an emphasis on mental health services for vulnerable populations.

Director Vincent Boehringer weaves a moving story of a young man’s declining mental health through the voicemails of his ...

Boehringer Ingelheim focuses on targeting the proteins involved in this process as a promising strategy for developing new cancer treatments. Credit: Tada Images/Shutterstock. Boehringer Ingelheim and ...

FRANKFURT (Reuters) – Denmark’s Zealand Pharma and German partner Boehringer Ingelheim have won the U.S. Food and Drug Administration’s Breakthrough Therapy for the review of their ...

FRANKFURT (Reuters) – Denmark’s Zealand Pharma and German partner Boehringer Ingelheim have won the U.S. Food and Drug Administration’s Breakthrough Therapy for the review of their experimental weight ...

Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for survodutide (BI 456906), a dual glucagon/GLP-1 receptor agonist 2 ...

3 In addition, Boehringer announced the initiation of two Phase III clinical trials for survodutide for the treatment of adults living with MASH and fibrosis (scarring). LIVERAGE will examine whether ...